Ethyl Lactate Ameliorates Hepatic Steatosis and Acute‐on‐Chronic Liver Injury in Alcohol‐Associated Liver Disease by Inducing Fibroblast Growth Factor 21
Advanced Science · 2025-02 · 12 (5)
DOI: 10.1002/advs.202409516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 11.12.2024. Verfasst von Yang Jiang und 19 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Food Nutrition and Safety, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China. Hauptthemen laut MEDLINE: Fibroblast Growth Factors, Liver Diseases, Alcoholic, Fatty Liver, Alcoholic, Fatty Liver. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shanghai Municipal Science and Technology Major Project, The Key R&D Program of Ningxia Hui Autonomous Region.
Abstract (Originalsprache)
Aberrant upregulation of hepatic lipogenesis induced by chronic and excessive alcohol consumption is a critical driver of the progression of alcohol‐associated liver disease (ALD), however, no effective approaches inhibiting lipogenesis are currently available for treating ALD patients. Moreover, little is known about whether and how nonethanol ingredients in alcoholic beverages regulate the pathogenesis of ALD. Here the discovery of a small molecule that activates the production and secretion of fibroblast growth factor 21 (FGF21) is reported. It is shown that the activator ethyl lactate, a nonethanol ingredient found in distilled liquors, ameliorates alcoholic hepatosteatosis, inflammation and acute‐on‐chronic liver injury by stimulating FGF21. In response to chronic‐plus‐binge ethanol feeding or fasting, ethyl lactate mimics lipogenesis lowering effects by stimulating FGF21 production through the NAD + ‐dependent deacetylase sirtuin 1 (SIRT1) signaling pathway. These ethyl lactate‐mediated beneficial effects are abolished by inhibition of SIRT1 through injection of EX527. Importantly, FGF21 deficiency in hepatocytes blocks the downregulation of lipogenesis by ethyl lactate and exacerbates alcoholic steatosis, inflammation and liver injury. The regulatory mechanism is discussed during the pathophysiological conditions and suggests new lines of research into the therapeutic use of a foodborne small molecule ethyl lactate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Food Nutrition and Safety, College of Biotechnology, Tianjin University of Science and Technology, Tianjin, 300457, China.
- CAS Key Laboratory of Nutrition, Metabolism and Food Safety, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
- CAS Engineering Laboratory for Nutrition, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, 200031, China.
- Sichuan Langjiu Co., Ltd, Gulin, Sichuan, 646523, China.
- Department of Endocrinology and Metabolism, Metabolic Vascular Disease Key Laboratory of Sichuan Province, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, 646000, China.
ORCID-Profile: Yu Li
Förderung
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Major Project
- The Key R&D Program of Ningxia Hui Autonomous Region
- China Alcoholic Drinks Association Project
- Sichuan Gulin Langjiu Co., Ltd. Project
- Tianjin Research Innovation Project for Postgraduate Students
- Open Project Program of Metabolic Vascular Diseases Key Laboratory of Sichuan Province
- General Program of Science and Technology Department of Sichuan Province
Zitieren
APA
Jiang, Y., Wei, S., Shen, S., Liu, Y., Su, W., Ding, D., Zheng, Z., Yu, H., Zhang, T., Yang, Q., Zhao, J., Shen, Y., Fang, X., Lin, L., Xiao, D., Cui, A., Wan, Q., Zhang, Y., Li, Y., & Zhang, C. (2025). Ethyl Lactate Ameliorates Hepatic Steatosis and Acute‐on‐Chronic Liver Injury in Alcohol‐Associated Liver Disease by Inducing Fibroblast Growth Factor 21. Advanced Science, 12(5). https://doi.org/10.1002/advs.202409516
Vancouver
Jiang Y, Wei S, Shen S, Liu Y, Su W, Ding D, et al. Ethyl Lactate Ameliorates Hepatic Steatosis and Acute‐on‐Chronic Liver Injury in Alcohol‐Associated Liver Disease by Inducing Fibroblast Growth Factor 21. Advanced Science. 2025;12(5). doi:10.1002/advs.202409516
BibTeX
@article{Jiang2025,
author = {Jiang, Yang and Wei, Shuang and Shen, Shiming and Liu, Yuxiao and Su, Weitong and Ding, Dong and Zheng, Zengpeng and Yu, Haokai and Zhang, Tingting and Yang, Qiuli and Zhao, Jiuxiang and Shen, Yi and Fang, Xia and Lin, Liangcai and Xiao, Dongguang and Cui, Aoyuan and Wan, Qin and Zhang, Yadong and Li, Yu and Zhang, Cuiying},
title = {Ethyl Lactate Ameliorates Hepatic Steatosis and Acute‐on‐Chronic Liver Injury in Alcohol‐Associated Liver Disease by Inducing Fibroblast Growth Factor 21},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {5},
doi = {10.1002/advs.202409516}
}
EUVIMED